Modulating carbohydrate–protein interactions through glycoengineering of monoclonal antibodies to impact cancer physiology. (October 2016)
- Record Type:
- Journal Article
- Title:
- Modulating carbohydrate–protein interactions through glycoengineering of monoclonal antibodies to impact cancer physiology. (October 2016)
- Main Title:
- Modulating carbohydrate–protein interactions through glycoengineering of monoclonal antibodies to impact cancer physiology
- Authors:
- Chiang, Austin WT
Li, Shangzhong
Spahn, Philipp N
Richelle, Anne
Kuo, Chih-Chung
Samoudi, Mojtaba
Lewis, Nathan E - Abstract:
- Graphical abstract: Highlights: Glycan–protein interactions modulate tumor cell killing. Different glycans can significantly alter the glycan–protein interactions. Glycan structure and location on mAb are essential properties need careful control. Glycoengineering can modify glycans on therapeutic mAbs with desired glycoforms. Systems biology can advance mAb glycoengineering toward a rational design era. Abstract : Diverse glycans on proteins impact cell and organism physiology, along with drug activity. Since many protein-based biotherapeutics are glycosylated and these glycans have biological activity, there is a desire to engineer glycosylation for recombinant protein-based biotherapeutics. Engineered glycosylation can impact the recombinant protein efficacy and also influence many cell pathways by first changing glycan–protein interactions and consequently modulating disease physiologies. However, its complexity is enormous. Recent advances in glycoengineering now make it easier to modulate protein-glycan interactions. Here, we discuss how engineered glycans contribute to therapeutic monoclonal antibodies (mAbs) in the treatment of cancers, how these glycoengineered therapeutic mAbs affect the transformed phenotypes and downstream cell pathways. Furthermore, we suggest how systems biology can help in the next generation mAb glycoengineering process by aiding in data analysis and guiding engineering efforts to tailor mAb glycan and ultimately drug efficacy, safety andGraphical abstract: Highlights: Glycan–protein interactions modulate tumor cell killing. Different glycans can significantly alter the glycan–protein interactions. Glycan structure and location on mAb are essential properties need careful control. Glycoengineering can modify glycans on therapeutic mAbs with desired glycoforms. Systems biology can advance mAb glycoengineering toward a rational design era. Abstract : Diverse glycans on proteins impact cell and organism physiology, along with drug activity. Since many protein-based biotherapeutics are glycosylated and these glycans have biological activity, there is a desire to engineer glycosylation for recombinant protein-based biotherapeutics. Engineered glycosylation can impact the recombinant protein efficacy and also influence many cell pathways by first changing glycan–protein interactions and consequently modulating disease physiologies. However, its complexity is enormous. Recent advances in glycoengineering now make it easier to modulate protein-glycan interactions. Here, we discuss how engineered glycans contribute to therapeutic monoclonal antibodies (mAbs) in the treatment of cancers, how these glycoengineered therapeutic mAbs affect the transformed phenotypes and downstream cell pathways. Furthermore, we suggest how systems biology can help in the next generation mAb glycoengineering process by aiding in data analysis and guiding engineering efforts to tailor mAb glycan and ultimately drug efficacy, safety and affordability. … (more)
- Is Part Of:
- Current opinion in structural biology. Volume 40(2016)
- Journal:
- Current opinion in structural biology
- Issue:
- Volume 40(2016)
- Issue Display:
- Volume 40, Issue 2016 (2016)
- Year:
- 2016
- Volume:
- 40
- Issue:
- 2016
- Issue Sort Value:
- 2016-0040-2016-0000
- Page Start:
- 104
- Page End:
- 111
- Publication Date:
- 2016-10
- Subjects:
- Molecular biology -- Periodicals
570 - Journal URLs:
- http://www.sciencedirect.com/science/journal/0959440X/ ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.sbi.2016.08.008 ↗
- Languages:
- English
- ISSNs:
- 0959-440X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3500.779000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 1241.xml